A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme. A significant portion of extensive metabolizers do not reach appropriate drug levels, and our objective was to investigate any genetic background.

[1]  H. Sugimura,et al.  Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. , 2001, Pharmacogenetics.

[2]  杉本 光繁.  Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status , 2006 .

[3]  M. Ingelman-Sundberg,et al.  S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. , 1996, Pharmacogenetics.

[4]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[5]  H. Nakabayashi,et al.  A position-dependent silencer plays a major role in repressing alpha-fetoprotein expression in human hepatoma , 1991, Molecular and cellular biology.

[6]  U. Brinkmann,et al.  Sequence diversity and functional characterization of the 5'-regulatory region of human CYP2C19. , 2003 .

[7]  L. Bertilsson,et al.  No sex‐related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects , 2000, Clinical pharmacology and therapeutics.

[8]  M. Ingelman-Sundberg,et al.  Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. , 2002, Pharmacogenetics.

[9]  L. Bertilsson,et al.  Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. , 2003, British journal of clinical pharmacology.

[10]  L. Bertilsson,et al.  Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. , 1995, Pharmacogenetics.

[11]  Ulrich Klotz,et al.  CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole‐based quadruple therapy for eradication of Helicobacter Pylori , 2004, Clinical pharmacology and therapeutics.

[12]  D. Charney,et al.  Treatment‐refractory depression: Definitions and characteristics , 1997, Depression and anxiety.

[13]  H. Mohrenweiser,et al.  Identification and functional characterization of new potentially defective alleles of human CYP2C19. , 2002, Pharmacogenetics.

[14]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[15]  R. A. Zeeuw,et al.  CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences , 1999, European Journal of Clinical Pharmacology.

[16]  Kyoichi Ohashi,et al.  Pharmacogenomics of proton pump inhibitors. , 2004, Pharmacogenomics.

[17]  K. Shimoda,et al.  Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data. , 1993, Journal of affective disorders.

[18]  L. Bertilsson,et al.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19. , 1995, British journal of clinical pharmacology.

[19]  Zhaoqian Liu,et al.  Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[20]  K Walsh,et al.  The human GATA-6 gene: structure, chromosomal location, and regulation of expression by tissue-specific and mitogen-responsive signals. , 1996, Genomics.

[21]  P. Nelemans,et al.  Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review , 2004, Molecular Psychiatry.

[22]  M. Ingelman-Sundberg,et al.  Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine , 2004, European Journal of Clinical Pharmacology.

[23]  Yoshiro Saito,et al.  Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. , 2004, Drug metabolism and pharmacokinetics.

[24]  K. Ohashi,et al.  Effect of high‐dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19 , 2001, Clinical pharmacology and therapeutics.

[25]  J. D. Engel,et al.  Hepatic Erythropoietin Gene Regulation by GATA-4* , 2004, Journal of Biological Chemistry.

[26]  L. Bertilsson,et al.  The karolinska cocktail for phenotyping of five human cytochrome P450 enzymes , 2003, Clinical pharmacology and therapeutics.

[27]  E. Sellers,et al.  Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker , 2002, Clinical pharmacology and therapeutics.

[28]  Daniel Levy,et al.  Regulation of human microsomal epoxide hydrolase gene (EPHX1) expression by the transcription factor GATA-4. , 2004, Biochimica et biophysica acta.

[29]  T. Koike,et al.  The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism , 2003, Alimentary pharmacology & therapeutics.

[30]  M. Kasuga,et al.  Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. , 2002, Biological & pharmaceutical bulletin.

[31]  A. Chow,et al.  Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability , 2004, Journal of clinical pharmacology.

[32]  D. Yim,et al.  Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19 , 2001, Clinical pharmacology and therapeutics.

[33]  H. Sackeim,et al.  Sertraline treatment of elderly patients with depression and cognitive impairment , 2003, International journal of geriatric psychiatry.

[34]  M. Relling,et al.  Pharmacogenomics: translating functional genomics into rational therapeutics. , 1999, Science.

[35]  L. Bertilsson,et al.  Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. , 2000, Gastroenterology.

[36]  H. Sugimura,et al.  Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. , 2000, Clinical pharmacology and therapeutics.

[37]  K. Ohashi,et al.  Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole , 2002, Clinical pharmacology and therapeutics.

[38]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[39]  Zhaoqian Liu,et al.  Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[40]  David B. Wilson,et al.  GATA-4, GATA-5, and GATA-6 activate the rat liver fatty acid binding protein gene in concert with HNF-1alpha. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[41]  K. Ohashi,et al.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH , 2001, Alimentary pharmacology & therapeutics.

[42]  T Ishizaki,et al.  CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. , 1998, Clinical pharmacology and therapeutics.

[43]  U. Klotz,et al.  CYP2C19 polymorphism and proton pump inhibitors. , 2004, Basic & clinical pharmacology & toxicology.

[44]  H. Sugimura,et al.  Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin , 2001 .